Current Report Filing (8-k)
July 27 2017 - 7:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): July 27, 2017
VBI
VACCINES INC.
(Exact
name of registrant as specified in its charter)
British
Columbia, Canada
|
|
000-37769
|
|
N/A
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
222
Third Street, Suite 2241
Cambridge,
Massachusetts
|
|
02142
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(617)
830-3031
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01 Regulation FD Disclosure.
On July 27, 2017, VBI Vaccines Inc. (the “Company”) will host a conference call and webcast to
discuss interim data from a Phase 1 study of its preventative CMV vaccine. A copy of the conference call presentation materials
is furnished hereto as Exhibit 99.1.
The
information disclosed under this Item 7.01, including Exhibit 99.1, hereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed “filed” with the U.S. Securities
and Exchange Commission nor incorporated by reference into any filing made under the Securities Act of 1933, as amended, except
as expressly set forth by specific reference in such filing.
Item
8.01 Other Events.
On July
27, 2017, the Company issued
a press release announcing interim data from the Phase 1 study of its preventative CMV vaccine. A copy of the press release is
attached as Exhibit 99.2 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
99.1*
|
|
July 27, 2017 Conference Call Presentation Materials
|
99.2
|
|
Press
Release dated July 27, 2017
|
* Furnished herewith
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
VBI
Vaccines Inc.
|
|
|
|
Date:
July 27, 2017
|
By:
|
/s/
Jeff Baxter
|
|
|
Jeff
Baxter
|
|
|
President
and Chief Executive Officer
|
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Apr 2023 to Apr 2024